- Home
- JL vs CANF Comparison
JL vs CANF Comparison
Compare JL & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JL
- CANF
- Stock Information
- Founded
- JL 1985
- CANF 1994
- Country
- JL Hong Kong
- CANF Israel
- Employees
- JL N/A
- CANF N/A
- Industry
- JL
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- JL
- CANF Health Care
- Exchange
- JL NYSE
- CANF Nasdaq
- Market Cap
- JL 13.7M
- CANF 14.4M
- IPO Year
- JL 2024
- CANF N/A
- Fundamental
- Price
- JL $0.39
- CANF $2.46
- Analyst Decision
- JL
- CANF Strong Buy
- Analyst Count
- JL 0
- CANF 2
- Target Price
- JL N/A
- CANF $14.00
- AVG Volume (30 Days)
- JL 294.5K
- CANF 137.2K
- Earning Date
- JL 11-02-2024
- CANF 11-15-2024
- Dividend Yield
- JL N/A
- CANF N/A
- EPS Growth
- JL N/A
- CANF N/A
- EPS
- JL 0.03
- CANF N/A
- Revenue
- JL $28,378,669.00
- CANF $667,000.00
- Revenue This Year
- JL N/A
- CANF $356.93
- Revenue Next Year
- JL N/A
- CANF N/A
- P/E Ratio
- JL $14.40
- CANF N/A
- Revenue Growth
- JL N/A
- CANF N/A
- 52 Week Low
- JL $0.30
- CANF $1.81
- 52 Week High
- JL $29.95
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- JL 49.58
- CANF 62.91
- Support Level
- JL $0.36
- CANF $1.87
- Resistance Level
- JL $0.44
- CANF $2.55
- Average True Range (ATR)
- JL 0.03
- CANF 0.17
- MACD
- JL -0.00
- CANF 0.06
- Stochastic Oscillator
- JL 40.82
- CANF 85.94
About JL J-LONG GROUP LIMITED
J-Long Group Ltd is an established distributor in Hong Kong of reflective and non-reflective garment trims including, among others, heat transfers, fabrics, woven labels and tapes, sewing badges, piping, zipper pullers and drawcords. It also offers a wide range of apparel solution services to cater to its customers' needs for reflective and non-reflective garment trims, ranging from market trend analysis, product design and development and production to quality control.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).